Supported by: Hear from leading expert Dr David DiGiusto, Stanford University School of Medicine, USA, as he shares his extensive experience in developing and optimizing manufacturing processes for cell and
gene therapy products including:
Not exact matches
Risk Versus Reward: The Value of Cell
Therapy for Patients and Investors Source: Streetwise Reports (4/25/18) The cell therapy space, encompassing disruptive new treatment including stem cell therapy, immunotherapy and gene editing, has begun to mature, with a handful of product approvals and others in late - stage devel
Therapy for Patients and Investors Source: Streetwise Reports (4/25/18) The cell
therapy space, encompassing disruptive new treatment including stem cell therapy, immunotherapy and gene editing, has begun to mature, with a handful of product approvals and others in late - stage devel
therapy space, encompassing disruptive new treatment
including stem cell
therapy, immunotherapy and gene editing, has begun to mature, with a handful of product approvals and others in late - stage devel
therapy, immunotherapy and
gene editing, has begun to mature, with a handful of
product approvals and others in late - stage development.
The cell
therapy space, encompassing disruptive new treatment
including stem cell
therapy, immunotherapy and
gene editing, has begun to mature, with a handful of
product approvals and others in late - stage development.
These
include the ability to bring new, innovative
products to the market; progress in oncology, such as the approval of Genentech's drug Avastin for breast cancer and advances in the use of
gene therapy, despite some setbacks; continuing progress in research on stem cells; the emergence of treatments for previously untreated diseases; and solutions for food and fuel shortages, such as biocrops and biofuels.
FDA also approves so - called biologics, which
include products made from human tissues, blood, and cells, and
gene therapy techniques.
China has made crucial breakthroughs in the field,
including creating the world's first commercialized
gene therapy product, Gendicine.
Among other things, we plan to
include certain
gene therapy products that permanently alter tissue and produce a sustained therapeutic benefit as part of the
products that will meet the definition of being eligible to come under the pathway enabled by RMAT.
GlaxoSmithKline has sold a number of
gene therapy products —
including its approved autologous ex vivo
product Strimvelis — to Orchard Therapeutics.
In addition to its emphasis on producing vaccines, the lab specializes in
gene and cell
therapies,
including stem cell
products.
Preparation and global prosecution of patent applications directed to diagnostic and therapeutic
products including antibodies,
gene therapies, vaccines, stem cells, pharmaceutical formulations, nanotechnology, nucleic acid molecules, biologics, medical devices, mouse platforms for antibody development, and methods of treating diseases.